Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by HighSkies2019on Apr 08, 2021 7:55pm
305 Views
Post# 32964126

Another NR on Name and Ticker change

Another NR on Name and Ticker changeThere's another nr out on stockwatch confirming name and ticker code to start trading on April 12 under new ticker...but I also saw this..... TSX Venture Exchange Stock Maintenance Bulletins NEWS PROVIDED BY TSX Venture Exchange Apr 08, 2021, 18:52 ET VANCOUVER, BC, April 8, 2021 /CNW/ - TSX VENTURE COMPANIES CLARITAS PHARMACEUTICALS, INC. ("CLAS") ("CLAS.WT.A") ("CLAS.WT.B") [formerly KALYTERA THERAPEUTICS, INC. ("KLY") ("KLY.WT.A") ("KLY.WT.B")] BULLETIN TYPE: Name Change BULLETIN DATE: April 8, 2021 TSX Venture Tier 2 Company Pursuant to a resolution passed by directors on February 26, 2021, the Company has changed its name as follows. There is no consolidation of capital. Effective at the opening on Monday, April 12, 2021, the common shares and warrants of Claritas Pharmaceuticals, Inc. will commence trading on TSX Venture Exchange, and the common shares and warrants of Kalytera Therapeutics, Inc. will be delisted. The Company is classified as a 'Research And Development In The Life Sciences' company. Capitalization: Unlimited shares with no par value of which 546,075,967 shares are issued and outstanding Escrow: Nil shares are subject to escrow Transfer Agent: TSX Trust Company Common Shares Trading Symbol: CLAS (new) CUSIP Number: 180634 10 7 (new) Series of warrants set to expire on August 8, 2021 Trading Symbol: CLAS.WT.A (new) CUSIP Number: 180634 11 5 (new) Series of warrants set to expire on April 26, 2022 Trading Symbol: CLAS.WT.B (new) CUSIP Number: 180634 12 3
<< Previous
Bullboard Posts
Next >>